Literature DB >> 23479355

Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay.

Lorna M Cryan1, Kaiane A Habeshian, Thomas P Caldwell, Meredith T Morris, P Christine Ackroyd, Kenneth A Christensen, Michael S Rogers.   

Abstract

Tumor marker endothelial 8 (TEM8) is a receptor for the protective antigen (PA) component of anthrax toxin. TEM8 is upregulated on endothelial cells lining the blood vessels within tumors, compared with normal blood vessels. A number of studies have demonstrated a pivotal role for TEM8 in developmental and tumor angiogenesis. We have also shown that targeting the anthrax receptors with a mutated form of PA inhibits angiogenesis and tumor formation in vivo. Here we describe the development and testing of a high-throughput fluorescence resonance energy transfer assay to identify molecules that strongly inhibit the interaction of PA and TEM8. The assay we describe is sensitive and robust, with a Z' value of 0.8. A preliminary screen of 2310 known bioactive library compounds identified ebselen and thimerosal as inhibitors of the TEM8-PA interaction. These molecules each contain a cysteine-reactive transition metal, and complementary studies indicate that their inhibition of interaction is due to modification of a cysteine residue in the TEM8 extracellular domain. This is the first demonstration of a high-throughput screening assay that identifies inhibitors of TEM8, with potential application for antianthrax and antiangiogenic diseases.

Entities:  

Keywords:  FRET; angiogenesis; anthrax; high-throughput screening; tumor endothelial marker 8

Mesh:

Substances:

Year:  2013        PMID: 23479355      PMCID: PMC3859190          DOI: 10.1177/1087057113478655

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  31 in total

1.  Genes expressed in human tumor endothelium.

Authors:  B St Croix; C Rago; V Velculescu; G Traverso; K E Romans; E Montgomery; A Lal; G J Riggins; C Lengauer; B Vogelstein; K W Kinzler
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

2.  TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types.

Authors:  Amit Chaudhary; Mary Beth Hilton; Steven Seaman; Diana C Haines; Susan Stevenson; Peter K Lemotte; William R Tschantz; Xiaoyan M Zhang; Saurabh Saha; Tony Fleming; Brad St Croix
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

3.  Cell surface tumor endothelial markers are conserved in mice and humans.

Authors:  E B Carson-Walter; D N Watkins; A Nanda; B Vogelstein; K W Kinzler; B St Croix
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Ligand binding to integrin alphaIIbbeta3 is dependent on a MIDAS-like domain in the beta3 subunit.

Authors:  E C Tozer; R C Liddington; M J Sutcliffe; A H Smeeton; J C Loftus
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

5.  The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin.

Authors:  Sheng Fu; Xiaohang Tong; Chenguang Cai; Ying Zhao; Yang Wu; Yuanyuan Li; Junjie Xu; Xuejun C Zhang; Long Xu; Wei Chen; Zihe Rao
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

6.  Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions.

Authors:  Kenneth A Bradley; Jeremy Mogridge; G Jonah; A Rainey; Sarah Batty; John A T Young
Journal:  J Biol Chem       Date:  2003-09-24       Impact factor: 5.157

7.  Interaction of ebselen with glutathione S-transferase and papain in vitro.

Authors:  T Nikawa; G Schuch; G Wagner; H Sies
Journal:  Biochem Pharmacol       Date:  1994-03-15       Impact factor: 5.858

8.  Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase.

Authors:  A Zembowicz; R J Hatchett; W Radziszewski; R J Gryglewski
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

9.  A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.

Authors:  Michael S Rogers; Lorna M Cryan; Kaiane A Habeshian; Lauren Bazinet; Thomas P Caldwell; P Christine Ackroyd; Kenneth A Christensen
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.

Authors:  Masatoshi Jinnin; Damian Medici; Lucy Park; Nisha Limaye; Yanqiu Liu; Elisa Boscolo; Joyce Bischoff; Miikka Vikkula; Eileen Boye; Bjorn R Olsen
Journal:  Nat Med       Date:  2008-10-19       Impact factor: 53.440

View more
  8 in total

Review 1.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 2.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

3.  Capillary morphogenesis gene 2 (CMG2) mediates growth factor-induced angiogenesis by regulating endothelial cell chemotaxis.

Authors:  Lorna M Cryan; Tsz-Ming Tsang; Jessica Stiles; Lauren Bazinet; Sai Lun Lee; Samuel Garrard; Erika Madrian; Cody Roberts; Jessie Payne; Andrew Jensen; Arthur E Frankel; P Christine Ackroyd; Kenneth A Christensen; Michael S Rogers
Journal:  Angiogenesis       Date:  2022-02-25       Impact factor: 10.658

4.  Monitoring the kinetics of the pH-driven transition of the anthrax toxin prepore to the pore by biolayer interferometry and surface plasmon resonance.

Authors:  Subhashchandra Naik; Susan Brock; Narahari Akkaladevi; Jon Tally; Wesley McGinn-Straub; Na Zhang; Phillip Gao; E P Gogol; B L Pentelute; R John Collier; Mark T Fisher
Journal:  Biochemistry       Date:  2013-09-09       Impact factor: 3.162

Review 5.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

6.  Developing a novel FRET assay, targeting the binding between Antizyme-AZIN.

Authors:  Aram Ghalali; James M Rice; Amanda Kusztos; Finith E Jernigan; Bruce R Zetter; Michael S Rogers
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

7.  The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75.

Authors:  Da-Wei Zhang; Hao-Li Yan; Xiao-Shuang Xu; Lei Xu; Zhi-Hui Yin; Shan Chang; Heng Luo
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 8.  Selenium and selenoproteins in viral infection with potential relevance to COVID-19.

Authors:  Jinsong Zhang; Ramy Saad; Ethan Will Taylor; Margaret P Rayman
Journal:  Redox Biol       Date:  2020-09-10       Impact factor: 11.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.